Vilon

Overview

Vilon is a synthetic dipeptide (Lys-Glu / KE) from the Khavinson bioregulator series, originally derived from thymus extracts and studied in Russian preclinical models as an immunomodulator and geroprotector. Not FDA-approved; all published evidence originates from a single research group.

Mechanism of Action

Proposed mechanism per the Khavinson model: KE penetrates cells and nuclei and modulates expression of immune- and senescence-related genes. Downstream pathways remain hypothetical; no validated receptor target has been identified.

Research Summary

Evidence is limited to Khavinson-group preclinical work. Khavinson & Anisimov (Dokl Biol Sci, 2000; PMID 10944717) reported that Vilon (L-Lys-L-Glu) inhibited spontaneous tumor growth and extended lifespan in CBA mice. A small Russian report on Vilon as an adjuvant in elderly colorectal-cancer patients (Kuznik et al., 2005; PMID 16075684) is non-randomized and unreplicated. No Western-framework clinical trials, pharmacokinetic, or dose-response studies have been published.

Dosing Information

Reported Side Effects

• Injection site irritation

Research References

• A synthetic dipeptide vilon (L-Lys-L-Glu) inhibits growth of spontaneous tumors and increases life span of mice (Khavinson & Anisimov) (2000)
• Application of peptide bioregulator Vilon in complex treatment of elderly cancer patients (2005)